Posts tagged “GSK”
GlaxoSmithKline says it has found no evidence of bribery involving its business in China following a four-month investigation. Earlier this week, the drug giant fired a scientist at its China R&D site after an internal investigation found that data in a research paper was misrepresented and should be retracted.
Glaxo acquires the rights to a German-based company's drug that is under clinical trial as a treatment for arthritis and multiple sclerosis. In other news, GSK reports the use of a breast cancer drug fails in a clinical trial as a treatment for gastic cancer.
The former blockbuster diabetes pill which was subjected to major safety restrictions in 2010 may not be as dangerous as once thought, according to the latest analysis of the much-debated GlaxoSmithKline drug.
Disease progression was delayed for a median of 17.9 months among patients taking Votrient, compared with 12.3 months among those on placebo, according to the study of 940 patients with advanced ovarian, fallopian tube and primary peritoneal cancer, GSK says.
In gaining regulatory approval on Tafinlar and Mekinist, GSK also gets steps into the arena for personalized medince skin cancer therapies, territory already staked out by Roche. Like Roche's Zelboraf, GSK's two new skin cancer drugs will be administered only to patients that have a particular gene mutation showing that the drug will work for them.
"This is a fantastic opportunity for patients and our research organisation as it is expected to contribute to the development efforts for an exciting new generation of vaccines, building on the excellent science and expertise of both companies," president of GSK Vaccines says.
"Price reductions are in many ways very important in driving the access and take-up of health-care coverage," Chief Financial Officer Simon Dingemans says. "We see very good volume response to that, which shows the strategy is working."
Elan will receive 21 percent of the royalties earned by Theravance from GlaxoSmithKline on the four respiratory medicines, and 20 percent of that income stream will be paid to Elan shareholders as a dividend.
Two drug giants with substantial operations in North Carolina are drastically cutting the costs of their cervical cancer vaccines as part of the first large-scale effort to get the shots to girls in the world's poorest areas.
Andrew Witty says Glaxo will sell off two popular nutritional drinks and reorganize how 50 major products are managed in order to drive more efficiency as the company continues to revamp its structure.
Drug giant GlaxoSmithKline will create a "distinct team" to oversee 50 "established products" and formally decides to sell off two nutritional drinks under CEO Andrew Witty's strategy that is revamping the company.
Imagine the incredible boost that $465 million in venture capital investment would do for Research Triangle Park's life science industry. Well, just imagine it because GlaxSmithKline, which operates its North American headquarters in RTP, is taking its investment deal to San Diego.